LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies
Biomedical Chromatography · 2023
DOI: 10.1002/bmc.5643 ↗At a glance
Journal article in Biomedical Chromatography, 2023. Written by Veenu Bala and 6 co-authors. Institution: Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA. Major MEDLINE topics: Tandem Mass Spectrometry, Nuclear Proteins. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS.
Abstract (original language)
A sensitive and selective liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantitation of dual PI3K/BRD4 inhibitor SF2523 in mouse plasma. The analysis was performed on a UPLC system connected to a Shimadzu 8060 mass spectrometer by electrospray ionization in positive multiple reaction monitoring mode. Chromatographic separation was carried out on an ACE Excel C 18 column with a gradient elution containing 0.1% formic acid and methanol as the mobile phase. The linearity was conducted in the concentration range 0.1–500 ng/ml for SF2523 in 100 μl of plasma. The inter‐ and intra‐batch precision (RSD) were both lower than 13.5%, with the accuracy (percentage bias) ranging from −10.03 to 11.56%. The validated method was successfully applied to plasma protein binding and in vitro metabolism studies. SF2523 was highly bound to mouse plasma proteins (>95% bound). Utilizing mouse S9 fractions, a total of seven phase I and II metabolites were identified with hydroxylation found to be the major metabolic pathway. Metabolite identification included analysis of retention behaviors, molecular weight changes and MS/MS fragment patterns of SF2523 and the metabolites. This newly developed and validated method allows the rapid and easy determination of the SF2523 concentration with high sensitivity in a low sample volume and can be applied to future pre‐clinical studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- SignalRx Pharmaceuticals, Inc., Cumming, Georgia, USA.
- Molecular Targeted Therapeutics Laboratory, Atrium Health-Levine Cancer Institute, Charlotte, North Carolina, USA.
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, North Carolina, USA.
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Moores Cancer Center, UC San Diego School of Medicine, La Jolla, California, USA.
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID profiles: Yashpal S Chhonker
Funding
- NCI NIH HHS
Cite
APA
Bala, V., Chhonker, Y. S., Morales, G. A., Maddeboina, K., Pal, D., Durden, D. L., & Murry, D. J. (2023). LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies. Biomedical Chromatography. https://doi.org/10.1002/bmc.5643
Vancouver
Bala V, Chhonker YS, Morales GA, Maddeboina K, Pal D, Durden DL, et al. LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies. Biomedical Chromatography. 2023. doi:10.1002/bmc.5643
BibTeX
@article{Bala2023,
author = {Bala, Veenu and Chhonker, Yashpal S and Morales, Guillermo A and Maddeboina, Krishnaiah and Pal, Dhananjaya and Durden, Donald L and Murry, Daryl J},
title = {LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies},
journal = {Biomedical Chromatography},
year = {2023},
doi = {10.1002/bmc.5643}
}
EUVIMED